Andrews MC, Chen WS, Spencer C, et al. Molecular, immune and microbial predictors of response and toxicity to combination immune-checkpoint blockade (CICB) in melanoma (MEL) patients. SMR 2017, abstract SMR02-3.
Adjuvant dabrafenib plus trametinib bij stadium III-melanoom: 10 jaar follow-up
aug 2024 | Dermato-oncologie